Has Amol Rakkar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $918,608 in general payments to Amol Rakkar, MD across 674 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amol Rakkar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amol Rakkar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amol Rakkar, MD

Hematology-Oncology · Glendale, AZNPI 1336160241

Payments from drug & device makers

$918,608in general payments, 2019–2025

Across 674 payments — averaging $1362.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$345K
Eli Lilly$191K
Seagen Inc.$141K
Mirati Therapeutics, Inc.$79K
Novartis$76K
Novocure GmbH$54K
plus $32K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	85	$344,743
Eli Lilly	8	$191,477
Seagen Inc.	18	$141,416
Mirati Therapeutics, Inc.	15	$79,024
Novartis	46	$75,903
Novocure GmbH	6	$53,609
Hexal AG	13	$10,000
Genentech, Inc.	1	$5,000
Jazz Pharmaceuticals Inc.	6	$4,099
E.r. Squibb & Sons, L.L.C.	54	$2,337
Daiichi Sankyo Inc.	16	$824
Bristol Myers Squibb	34	$723
Johnson & Johnson(2 entities)	35	$688
EMD Serono, Inc.	8	$666
Merck	29	$593
Genentech USA, Inc.	27	$516
AstraZeneca(2 entities)	20	$503
Spectrum Pharmaceuticals Inc.	1	$500
Amgen	25	$473
Incyte Corporation	20	$450
Lilly USA, LLC	14	$323
Gilead(2 entities)	14	$300
AbbVie	11	$257
Array Biopharma Inc	13	$256
AVEO Pharmaceuticals, Inc.	5	$241
Ipsen Biopharmaceuticals, Inc	6	$223
Exelixis Inc.	7	$182
Eisai Inc.	8	$178
Sumitomo Pharma America, Inc.	1	$177
Sanofi	8	$174
Astellas Pharma US Inc	9	$155
Stemline Therapeutics Inc.	6	$137
Karyopharm Therapeutics Inc.	3	$132
Pharmacyclics LLC, An Abbvie Company	6	$132
Bayer	6	$128
Genmab U.S., Inc.	3	$120
Blueprint Medicines Corporation	5	$113
Puma Biotechnology, Inc.	6	$103
GSK	6	$102
Sanofi-aventis U.S. LLC	1	$99
Tersera Therapeutics LLC	3	$98
Takeda Pharmaceuticals U.S.A., Inc.	4	$91
Servier Pharmaceuticals LLC	4	$91
Sun Pharmaceutical Industries Inc.	2	$87
Regeneron Healthcare Solutions, Inc.	4	$80
Rigel Pharmaceuticals, Inc.	3	$74
Boehringer Ingelheim	3	$71
Geron Corporation	2	$69
Sobi, Inc	3	$69
G1 Therapeutics, Inc.	3	$60
Beone Medicines USA, Inc.	2	$58
Beigene USA, Inc.	3	$56
Secura Bio, Inc.	3	$54
ADC Therapeutics America, Inc.	2	$47
Deciphera Pharmaceuticals Inc.	2	$43
Recordati_rare_diseases_inc.	1	$32
Pharming Healthcare, Inc.	1	$29
Agios Pharmaceuticals, Inc.	2	$29
Organon	2	$27
Adaptive Biotechnologies Corporation	1	$27

How this compares

Too few hematology-oncology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$5,921,968

Medicare patients

860

Services billed

267,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology-oncology in Glendale

James ChoiGlendale$4K
Madappa KundrandaGilbert$2.8M
Alejandro Recio BoilesTucson$2.5M
Navjeet GandhokPeoria$19K
Valerie IsraelLake Havasu City$4K
Madhuri KadiyalaChandler$865
Srivyshnavi NarraSun City$0

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →